

K080457

MAR 20 2008

510(k) Summary
as required by 807.92

1. Company Identification

EIZO NANA O CORPORATION
153 Shimokashiwano-cho, Hakusan-shi, Ishikawa-ken, 924-8566, Japan
Tel: +81-76-274-2468
Fax: +81-76-274-2484

2. Official Correspondent

Hiroaki Hashimoto (Mr.)
Manager of Engineering Management Section

3. Date of Submission

February 19, 2008

4. Device Trade name

Color LCD Monitor, RadiForce RX211

5. Common/Usual Name

Image display system, medical image workstation, image monitor/display, and others

6. Classification Number

Medical displays classified in Class II per 21 CFR 892.2050.

7. Predicate Device

Manufacturer : EIZO NANA O CORPORATION
Device Name : Color LCD Monitor
Model Name : RadiForce RX210
510(k) No. : K063120

8. Description of Device

RadiForce RX211 is a 54cm (21.3") Color LCD display for medical image viewing. RX211 displays high-definition medical imaging.

9. Intended Use

RadiForce RX211 is intended to be used in displaying and viewing digital images for diagnosis of X-ray or MRI, etc. by trained medical practitioners. RadiForce RX211 does not support the display of mammography images for diagnosis.

10. Technological Characteristics

RadiForce RX211 is substantially equivalent to RX210. RX211 employs the maximum resolution values same as that of RX210. RX211 improved the brightness of the LCD module, and modified the software. The brightness improved in 750 cd/m² from 600 cd/m². The contrast improved by it.

Comparison table of the principal characteristics of 2 devices is shown in the Attachment 1.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
9200 Corporate Blvd.
Rockville MD 20850

Mr. Hiroaki Hashimoto
Manager
EIZO NANA O CORPORATION
Engineering Management Section
153 Shimokashiwano-cho
Hakusan Ishikawa-ken 924-8566
JAPAN

MAR 20 2008

Re: K080457
Trade/Device Name: Color LCD Monitor, (RadiForce RX211)
Regulation Number: 21 CFR 892.2050
Regulation Name: Picture archiving and communications system
Regulatory Class: II
Product Code: LLZ
Dated: February 19, 2008
Received: February 20, 2008

Dear Mr. Hashimoto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



Protecting and Promoting Public Health

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number:

K080457

Device Name : Color LCD Monitor, RadiForce RX211

Indications for Use:

RadiForce RX211 is intended to be used in displaying and viewing digital images for diagnosis of X-ray or MRI, etc. by trained medical practitioners. RadiForce RX211 does not support the display of mammography images for diagnosis.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Jane M. Whang
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K080457